Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials - PubMed (original) (raw)
Meta-Analysis
Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials
Giuseppe Grosso et al. PLoS One. 2014.
Abstract
Background: Despite omega-3 polyunsaturated fatty acids (PUFA) supplementation in depressed patients have been suggested to improve depressive symptomatology, previous findings are not univocal.
Objectives: To conduct an updated meta-analysis of randomized controlled trials (RCTs) of omega-3 PUFA treatment of depressive disorders, taking into account the clinical differences among patients included in the studies.
Methods: A search on MEDLINE, EMBASE, PsycInfo, and the Cochrane Database of RCTs using omega-3 PUFA on patients with depressive symptoms published up to August 2013 was performed. Standardized mean difference in clinical measure of depression severity was primary outcome. Type of omega-3 used (particularly eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) and omega-3 as mono- or adjuvant therapy was also examined. Meta-regression analyses assessed the effects of study size, baseline depression severity, trial duration, dose of omega-3, and age of patients.
Results: Meta-analysis of 11 and 8 trials conducted respectively on patients with a DSM-defined diagnosis of major depressive disorder (MDD) and patients with depressive symptomatology but no diagnosis of MDD demonstrated significant clinical benefit of omega-3 PUFA treatment compared to placebo (standardized difference in random-effects model 0.56 SD [95% CI: 0.20, 0.92] and 0.22 SD [95% CI: 0.01, 0.43], respectively; pooled analysis was 0.38 SD [95% CI: 0.18, 0.59]). Use of mainly EPA within the preparation, rather than DHA, influenced final clinical efficacy. Significant clinical efficacy had the use of omega-3 PUFA as adjuvant rather than mono-therapy. No relation between efficacy and study size, baseline depression severity, trial duration, age of patients, and study quality was found. Omega-3 PUFA resulted effective in RCTs on patients with bipolar disorder, whereas no evidence was found for those exploring their efficacy on depressive symptoms in young populations, perinatal depression, primary disease other than depression and healthy subjects.
Conclusions: The use of omega-3 PUFA is effective in patients with diagnosis of MDD and on depressive patients without diagnosis of MDD.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
Similar articles
- Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder.
Mocking RJ, Harmsen I, Assies J, Koeter MW, Ruhé HG, Schene AH. Mocking RJ, et al. Transl Psychiatry. 2016 Mar 15;6(3):e756. doi: 10.1038/tp.2016.29. Transl Psychiatry. 2016. PMID: 26978738 Free PMC article. - Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression.
Sublette ME, Ellis SP, Geant AL, Mann JJ. Sublette ME, et al. J Clin Psychiatry. 2011 Dec;72(12):1577-84. doi: 10.4088/JCP.10m06634. Epub 2011 Sep 6. J Clin Psychiatry. 2011. PMID: 21939614 Free PMC article. - The role of n-3 polyunsaturated fatty acids (n-3PUFAs) in affective disorders.
Ciappolino V, Delvecchio G, Agostoni C, Mazzocchi A, Altamura AC, Brambilla P. Ciappolino V, et al. J Affect Disord. 2017 Dec 15;224:32-47. doi: 10.1016/j.jad.2016.12.034. Epub 2016 Dec 30. J Affect Disord. 2017. PMID: 28089169 Review. - Omega-3 polyunsaturated fatty acid (n-3 PUFA) supplementation for prevention and treatment of perinatal depression: a systematic review and meta-analysis of randomized-controlled trials.
Suradom C, Suttajit S, Oon-Arom A, Maneeton B, Srisurapanont M. Suradom C, et al. Nord J Psychiatry. 2021 May;75(4):239-246. doi: 10.1080/08039488.2020.1843710. Epub 2020 Nov 15. Nord J Psychiatry. 2021. PMID: 33190574
Cited by
- Omega-3 Polyunsaturated Fatty Acids in Depression.
Serefko A, Jach ME, Pietraszuk M, Świąder M, Świąder K, Szopa A. Serefko A, et al. Int J Mol Sci. 2024 Aug 8;25(16):8675. doi: 10.3390/ijms25168675. Int J Mol Sci. 2024. PMID: 39201362 Free PMC article. Review. - Omega-3 fatty acids and major depression: a Mendelian randomization study.
Carnegie R, Borges MC, Jones HJ, Zheng J, Haycock P, Evans J, Martin RM. Carnegie R, et al. Transl Psychiatry. 2024 May 29;14(1):222. doi: 10.1038/s41398-024-02932-w. Transl Psychiatry. 2024. PMID: 38811538 Free PMC article. - Nutraceuticals in Psychiatric Disorders: A Systematic Review.
Bozzatello P, Novelli R, Montemagni C, Rocca P, Bellino S. Bozzatello P, et al. Int J Mol Sci. 2024 Apr 28;25(9):4824. doi: 10.3390/ijms25094824. Int J Mol Sci. 2024. PMID: 38732043 Free PMC article. - Amygdalar neurotransmission alterations in the BTBR mice model of idiopathic autism.
Bove M, Palmieri MA, Santoro M, Agosti LP, Gaetani S, Romano A, Dimonte S, Costantino G, Sikora V, Tucci P, Schiavone S, Morgese MG, Trabace L. Bove M, et al. Transl Psychiatry. 2024 Apr 17;14(1):193. doi: 10.1038/s41398-024-02905-z. Transl Psychiatry. 2024. PMID: 38632257 Free PMC article. - Association of healthy eating index (2015) with depression and anxiety symptoms among Iranian adolescent girls.
Ghanbarzadeh E, Dorosty Motlagh AR, Abbasi B. Ghanbarzadeh E, et al. J Health Popul Nutr. 2024 Apr 2;43(1):44. doi: 10.1186/s41043-024-00529-z. J Health Popul Nutr. 2024. PMID: 38566258 Free PMC article.
References
- Kotwal S, Jun M, Sullivan D, Perkovic V, Neal B (2012) Omega 3 Fatty acids and cardiovascular outcomes: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 5: 808–818. - PubMed
- Machado-Vieira R, Mallinger AG (2012) Abnormal function of monoamine oxidase-A in comorbid major depressive disorder and cardiovascular disease: pathophysiological and therapeutic implications (review). Mol Med Rep 6: 915–922. - PubMed
- Severus WE, Littman AB, Stoll AL (2001) Omega-3 fatty acids, homocysteine, and the increased risk of cardiovascular mortality in major depressive disorder. Harv Rev Psychiatry 9: 280–293. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
Giuseppe Grosso and Sabrina Castellano were supported by the International Ph.D. Program in Neuropharmacology, University of Catania, Catania, Italy. The contributors had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials